Siberian State Medical University
Neurology and neurosurgery department

Author Of 1 Presentation

Prognostic Factors Late Breaking Abstracts

LB1187 - Evaluation of multiple sclerosis progression with clinic parameters in Tomsk Region, Russian Federation (ID 1986)

Speakers
Presentation Number
LB1187
Presentation Topic
Prognostic Factors

Abstract

Background

Progression of multiple sclerosis (MS) is a low modified process. An effective way to prevent MS progression is to choose an appropriate disease modified treatment (DMT), but there is no evidence-based approach to using non-drug methods. Mostly it is connected with high life quality in MS patients, which approve the ability to change twenty- or thirty- years prognosis for MS patients. In that way, the investigation of MS progression becomes is a scientific and clinical trend.

Objectives

The study aims to evaluate MS progression in different duration and disease activity with the use of clinic parameters.

Methods

In this observational study, 13 MS patients (female n=8, male n=5) with a relapse-remitting course (RRMS) participated. The average age was 33±5 [21-44] years, and the MS duration median was 4,7 (2,8; 6,9). Participants were evaluated with Montreal Cognitive Assessment (MoCa); the median was 26 (22; 26). Also, MS duration, age of MS debut, the annual average frequency of relapses, rate of progression (score of expanded disability status (EDSS)/ MS duration), annual average cognitive loss (level of deficit in MoCa/ MS duration). Spearman coefficient was used for statistical analysis of correlation.

Results

There were found statistical significant correlation between rate of MS progression and disease duration (p=0,001; k=-0,809), number of relapses (p<0,001; k=-0,827). A positive correlation was found between the MS progression rate and annual average rate of cognitive loss (p=0,011; 0,676).

Conclusions

The results show that the rate of MS progression decreases due to an increase in the MS duration and the number of relapses. At the moment of this study, seven patients have taken DMT. It influences the results because an increase in MS duration will lead to an increased chance of DMT taking. It is interesting to note that the linear correlation between the rate of MS progression and annual average cognitive loss was found in patients with the MS duration ranging from one year. In that way, the rate of cognitive loss correlates with the rate of MS progression and are existing at the early stages of RRMS. The theory of «cognitive reserve» and «brain reserve» can help understand the probability of cognitive and motor deficit management by non-drug measures for modifiable risk factors.

Collapse